From: Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
Target | Agent | Mechanism of action (B cells) | Developmental status |
---|---|---|---|
BAFF/BLyS | Belimumab (Anti-BlyS) | Partial B-cell depletion | Approved for SLE |
BAFF and APRIL | Atacicept (TACI-Ig) | Â | Phase I/II for RA, phase II/III for SLE |
TNFα/lymphotoxin-β | Etanercept | Disruption of germinal centers | Approved for RA, SpA, JIA and PsA |
IL-6 receptor | Tocilizumab | Blocks of B-cell and plasma cell differentiation | Approved for RA, JIA and Castleman's disease, phase I for SLE reported |
Type I interferon | MEDI 545 | Blocks plasma cell production | Phase II for SLE |
 | RhuMAb IFNα |  | Phase II for SLE |